List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.1. Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) |
Others observations: Not recommended for anti-inflammatory use due to lack of proven benefit to that effect. |
WHO Model List of Essential Medicines (2021) | 7.1. For treatment of acute attack |
This medicine is only for children. |
Training CSamouge 2022 | 2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) |
Others observations: Not recommended for anti-inflammatory use due to lack of proven benefit to that effect |
List | Section | Observation |
---|---|---|
Colombia | 13.2 Non-Narcotic Analgesics | No observations |
List | Section | Observation |
---|---|---|
Bolivia | LINAME 2011 - 2013 | No observations |
List | Section | Observation |
---|---|---|
Peru | 2.1 Non-Opiate Analgesics and Non-Steroidal Anti-Inflammatories (NSAIDs) | No observations |
Peru | 7.1 For Treatment of Acute Attacks | No observations |
Ecuador | Essential Medicines List - Ecuador | No observations |
Cuba | 2.1 Analgésicos no opioides | No observations |
Cuba | 7.1 Tratamiento del ataque agudo | No observations |
Training CSamouge 2022 | 2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) |
Others observations: Not recommended for anti-inflammatory use due to lack of proven benefit to that effect |
WHO Model List of Essential Medicines (2021) | 7.1. For treatment of acute attack |
This medicine is only for children. |
List | Section | Observation |
---|---|---|
Colombia | 13.2 Non-Narcotic Analgesics | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.1. Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) |
Others observations: Not recommended for anti-inflammatory use due to lack of proven benefit to that effect. |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.1. Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) |
Others observations: Not recommended for anti-inflammatory use due to lack of proven benefit to that effect. |
Bolivia | LINAME 2011 - 2013 | No observations |
Training CSamouge 2022 | 2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) |
Others observations: Not recommended for anti-inflammatory use due to lack of proven benefit to that effect |
List | Section | Observation |
---|---|---|
Peru | 2.1 Non-Opiate Analgesics and Non-Steroidal Anti-Inflammatories (NSAIDs) | No observations |
List | Section | Observation |
---|---|---|
Chile | Essential and Prioritized Medications | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.1. Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) |
Others observations: Not recommended for anti-inflammatory use due to lack of proven benefit to that effect. |
Training CSamouge 2022 | 2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) |
Others observations: Not recommended for anti-inflammatory use due to lack of proven benefit to that effect |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 7.1. For treatment of acute attack | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.1. Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) | No observations |
WHO Model List of Essential Medicines (2021) | 7.1. For treatment of acute attack | No observations |
Bolivia | LINAME 2011 - 2013 | No observations |
Peru | 2.1 Non-Opiate Analgesics and Non-Steroidal Anti-Inflammatories (NSAIDs) | No observations |
Peru | 7.1 For Treatment of Acute Attacks | No observations |
Cuba | 2.1 Analgésicos no opioides | No observations |
List | Section | Observation |
---|---|---|
Chile | Essential and Prioritized Medications | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 2.1. Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) | No observations |
WHO Model List of Essential Medicines (2021) | 7.1. For treatment of acute attack | No observations |